Spots Global Cancer Trial Database for faslodex
Every month we try and update this database with for faslodex cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Fulvestrant in Metastatic Breast Cancer | NCT03591549 | Metastatic Brea... | Faslodex Zoladex | 30 Years - 55 Years | Assiut University | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer | NCT00272740 | Breast Neoplasm... | Fulvestrant | - | AstraZeneca | |
| Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | NCT00138125 | Breast Cancer | Faslodex Herceptin | 18 Years - | Translational Oncology Research International | |
| SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer | NCT00272740 | Breast Neoplasm... | Fulvestrant | - | AstraZeneca | |
| Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | NCT01509625 | Malignant Neopl... | Fulvestrant | 18 Years - 80 Years | Hospital Clinico Universitario San Cecilio | |
| Fulvestrant in Metastatic Breast Cancer | NCT03591549 | Metastatic Brea... | Faslodex Zoladex | 30 Years - 55 Years | Assiut University | |
| Faslodex Post Marketing Surveillance | NCT00860561 | Breast Cancer | - | AstraZeneca | ||
| Faslodex Post Marketing Surveillance | NCT00860561 | Breast Cancer | - | AstraZeneca | ||
| Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) | NCT00880711 | Breast Cancer | - | AstraZeneca | ||
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | NCT01509625 | Malignant Neopl... | Fulvestrant | 18 Years - 80 Years | Hospital Clinico Universitario San Cecilio | |
| Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | NCT03531645 | Malignant Neopl... | Fulvestrant Abemaciclib | 18 Years - | M.D. Anderson Cancer Center | |
| Quality Of Life While Receiving Faslodex | NCT00643513 | Breast Cancer | 18 Years - | AstraZeneca | ||
| Faslodex 500mg Multiple Dose Tolerability Study in BC Patients | NCT00328120 | Advanced Breast... | Fulvestrant | 18 Years - | AstraZeneca | |
| SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer | NCT00272740 | Breast Neoplasm... | Fulvestrant | - | AstraZeneca | |
| Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | NCT00138125 | Breast Cancer | Faslodex Herceptin | 18 Years - | Translational Oncology Research International | |
| Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | NCT01797120 | Metastatic Brea... | Fulvestrant Everolimus Placebo | 18 Years - | PrECOG, LLC. | |
| Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer | NCT00878930 | Breast Cancer | 18 Years - | AstraZeneca | ||
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Faslodex Specific Clinical Experience Investigation | NCT01501266 | Breast Cancer | - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
